IL162822A0 - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
IL162822A0
IL162822A0 IL16282203A IL16282203A IL162822A0 IL 162822 A0 IL162822 A0 IL 162822A0 IL 16282203 A IL16282203 A IL 16282203A IL 16282203 A IL16282203 A IL 16282203A IL 162822 A0 IL162822 A0 IL 162822A0
Authority
IL
Israel
Prior art keywords
treatment
sexual dysfunction
male sexual
male
dysfunction
Prior art date
Application number
IL16282203A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL162822A0 publication Critical patent/IL162822A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL16282203A 2002-01-31 2003-01-20 Treatment of male sexual dysfunction IL162822A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
IL162822A0 true IL162822A0 (en) 2005-11-20

Family

ID=9930155

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16282203A IL162822A0 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
IL162822A IL162822A (en) 2002-01-31 2004-07-01 Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162822A IL162822A (en) 2002-01-31 2004-07-01 Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis

Country Status (16)

Country Link
EP (1) EP1470115A1 (ja)
JP (3) JP2005525321A (ja)
KR (2) KR100829262B1 (ja)
CN (1) CN100500658C (ja)
AU (1) AU2003201471B2 (ja)
BR (1) BR0307337A (ja)
CA (1) CA2474590A1 (ja)
GB (1) GB0202282D0 (ja)
HK (1) HK1073109A1 (ja)
IL (2) IL162822A0 (ja)
MX (1) MXPA04007434A (ja)
NZ (1) NZ546408A (ja)
PL (1) PL371415A1 (ja)
TW (1) TW200302732A (ja)
WO (1) WO2003064402A1 (ja)
ZA (1) ZA200405208B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
EP0679084A1 (en) * 1992-12-23 1995-11-02 Merck & Co. Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0614894A1 (en) * 1993-03-12 1994-09-14 Merck & Co. Inc. Process for the synthesis of substituted amide derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
CA2474590A1 (en) 2003-08-07
JP2010209075A (ja) 2010-09-24
NZ546408A (en) 2007-10-26
KR20040079958A (ko) 2004-09-16
IL162822A (en) 2010-11-30
JP2013151511A (ja) 2013-08-08
MXPA04007434A (es) 2004-10-11
JP2005525321A (ja) 2005-08-25
KR20080011232A (ko) 2008-01-31
ZA200405208B (en) 2005-08-31
KR100829262B1 (ko) 2008-05-13
WO2003064402A1 (en) 2003-08-07
CN1625553A (zh) 2005-06-08
AU2003201471B2 (en) 2009-03-26
TW200302732A (en) 2003-08-16
CN100500658C (zh) 2009-06-17
BR0307337A (pt) 2004-12-07
HK1073109A1 (en) 2005-09-23
PL371415A1 (en) 2005-06-13
GB0202282D0 (en) 2002-03-20
EP1470115A1 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
PL377729A1 (pl) Sposób leczenia dysfunkcji seksualnej
IL153492A0 (en) Treatment of male sexual dysfunction
AU2003248888A8 (en) Peptide composition for treatment of sexual dysfunction
IL137569A0 (en) Treatment of female sexual dysfunction
GB0225908D0 (en) Treatment of female sexual dysfunction
ZA200410009B (en) Compositions and methods for ameliorating of human female sexual dysfunction
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
GB2408558B (en) Treatment of pipes
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
EP1648430A4 (en) TREATMENT FOR EJACULATIO PRAECOX
GB2386555B (en) Treatment of female sexual dysfunction
IL166273A0 (en) Methods of treatment of male erectile dysfunction
GB0130219D0 (en) Compounds for the treatment of sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2003260818A8 (en) Treatment of immune system dysfunction
AP2004003174A0 (en) Treatment of water
IL162822A0 (en) Treatment of male sexual dysfunction
GB0120679D0 (en) Treatment of male sexual dysfunction
GB0108483D0 (en) Treatment of male sexual dysfunction
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction
GB0316673D0 (en) Treatment of female sexual dysfunction
GB0221712D0 (en) Methods of treatment